Michael Ryskin

“But we see strong momentum with China continuing to the year end and we're increasing our guide from high mid single digits to from flat and our q4 guidance is high single digits okay and my my follow-ups on cam actually you touched on a little bit in your in your comments right there you talked about you know applied…”

“Maybe a high-level one for me, high-level maybe broad, but just focusing on the total clinical volume, nice to see the bounce back, nice to see the step up in the quarter.”

“One is on the scanner, you touched on sort of some of the awareness and some of the macro CapEx environment impacting docs, but there's also been some incremental competition in the space from a handful of others with launches in the last three or six months.”

“I want to follow up on BMP, sort of like pacing through the rest of the year. You kind of talked about, you know, improving third quarter up a little bit, fourth quarter, then the fourth quarter just based on timing and comps.”

“I kind of want to follow up on just the last one. Thinking about your future investment and your future opportunities there. Like you said, you have been talking about AI for a number of years now.”